They claim “Embryonic stem cell lines are not Embryos”, they are derived from supernumerary embryos from IVF treatments and donated to research. Resulting cells can be maintained in culture indefinitely to produce cell banks but are clearly unable to produce an embryo. The fear of embryo commercialization is simply irrelevant.
It is also a scientific mistake to suggest that induced pluripotent stem cells (iPS) may – under the current scientific knowledge – replace embryonic stem cells in cell therapies.
A ban on embryonic stem cells patents would result in European discoveries being exploited elsewhere in the world. It seems unlikely that European patients would be excluded from such future medicines. In consequence, European public health care systems will have to import the applications of its very own discoveries.